配股融资

Search documents
昇柏控股拟折让约16.46%配股 最多净筹约1687万港元
Zhi Tong Cai Jing· 2025-09-30 13:06
昇柏控股(02340)公布,于2025年9月30日(交易时段后),公司与配售代理订立配售协议,据此公司有条 件同意透过配售代理按尽力基准以配售价每股配售股份港币0.137元向不少于六名承配人(为独立第三方 专业人士、机构或其他投资者)配售最多127,448,000股配售股份,配售价较股份于配售协议日期在联交 所所报收市价每股港币0.164元折让约16.46%。 假设所有配售股份均获悉数配售,净筹约1687万港元。约29.64%用于支付专业机构费用,约70.36%用 于集团的一般营运资金。 ...
上善黄金拟折让约19.88%配股 最高净筹约2.458亿港元
Zhi Tong Cai Jing· 2025-09-30 00:45
假设全部3782.54万股配售股份均获成功配售,配售所得款项总额将约为2.47亿港元,而配售所得款项净 额估计约为2.458亿港元。公司拟将所得款项净额用于以下用途:(i)9800万港元用于全球渠道布局及品 牌体系建设;(ii)9800万港元用于技术升级及供应链保障体系建设;(iii)4980万港元用于全球总部建设、全 球管理团队组建及其他一般营运开支。 上善黄金(01939)发布公告,于2025年9月29日,公司拟配售最多3782.54万股配售股份,相当于经悉数配 发及发行配售股份扩大后的已发行股份总数约7.03%。每股配售股份6.53港元的配售价,较9月29日收市 价每股8.150港元折让约19.88%。 ...
小鱼盈通拟折让约11%配股最多净筹约5000万港元
Zhi Tong Cai Jing· 2025-09-26 11:07
假设所有配售股份获悉数配售,净筹约5000万港元,拟用于清偿集团负债及用作集团一般营运资金。 小鱼盈通(00139)公布,于2025年9月26日,该公司拟透过配售代理向不少于六名承配人配售最多约2.05 亿股配售股份,配售价为每股配售股份0.25港元,较2025年9月26日在联交所所报收市价每股0.280港元 折让约11%。 ...
小鱼盈通(00139)拟折让约11%配股最多净筹约5000万港元
智通财经网· 2025-09-26 11:06
假设所有配售股份获悉数配售,净筹约5000万港元,拟用于清偿集团负债及用作集团一般营运资金。 智通财经APP讯,小鱼盈通(00139)公布,于2025年9月26日,该公司拟透过配售代理向不少于六名承配 人配售最多约2.05亿股配售股份,配售价为每股配售股份0.25港元,较2025年9月26日在联交所所报收市 价每股0.280港元折让约11%。 ...
圣诺医药-B(02257.HK)拟折价近20%配股总筹2.08亿港元,华熙生物等参与认购
Ge Long Hui· 2025-09-07 23:09
Group 1 - The company, Sanofi Pharmaceutical-B (02257.HK), announced a subscription agreement to issue 17.3524 million shares at a subscription price of HKD 12.00 per share [1] - The total shares to be issued represent approximately 16.50% of the company's existing issued share capital and about 14.16% of the enlarged issued share capital after the issuance [1] - The subscription price of HKD 12.00 per share reflects a discount of approximately 19.84% compared to the closing price of HKD 14.97 on September 5, the last trading day before the agreement [1] Group 2 - The total proceeds from the subscription are expected to be approximately HKD 208.2 million, with net proceeds around HKD 206 million [1] - The company plans to use the proceeds from the subscription for general working capital [1] - The subscribers include Huaxi Biotechnology (Hong Kong) Co., Ltd., Mr. Xie Shuohao, Bamboo Bloom Limited, and Capstone Resources Holding Limited [1]
药明合联(02268)拟按每股58.85港元配股 最多净筹约13.01亿港元
智通财经网· 2025-09-02 22:35
Core Viewpoint - WuXi AppTec (02268) has entered into a placement agreement to issue up to 22.277 million shares at a price of HKD 58.85 per share, potentially raising approximately HKD 1.311 billion in total proceeds [1] Group 1: Placement Details - The placement is conditional and will be conducted through a placement agent to at least six independent third-party investors [1] - If fully subscribed, the net proceeds from the placement are expected to be around HKD 1.301 billion [1] Group 2: Use of Proceeds - Approximately 90% of the proceeds will be allocated to expanding the company's service capabilities and production capacity, including clinical and commercial production of antibody-drug conjugates and active pharmaceutical ingredients [1] - The remaining 10% will be used for working capital needs and general corporate purposes [1]
PACIFIC LEGEND(08547)拟溢价约6.36%配股最多净筹约3800万港元
Zhi Tong Cai Jing· 2025-08-29 16:42
Group 1 - The company PACIFIC LEGEND (08547) plans to issue up to 82,107,900 shares at a price of HKD 0.468 per share, representing a premium of approximately 6.36% over the closing price of HKD 0.440 on the same day [1] - The maximum net proceeds from this placement are expected to be around HKD 38 million, which will be used for the company's working capital [1]
科笛折让12%配股筹2.4亿港元
Ge Long Hui A P P· 2025-08-29 01:34
Group 1 - The company plans to issue 28.904 million new shares, representing approximately 8.3% of the enlarged share capital [1] - The subscription price is set at HKD 8.4 per share, which is a discount of 12.04% compared to the closing price of HKD 9.55 yesterday [1] - The total fundraising amount is expected to be HKD 243 million [1] Group 2 - Approximately 45% of the net proceeds from the placement will be allocated to preclinical research and clinical trials for localized fat accumulation management, hair diseases and care, skin diseases and care, and epidermal anesthesia pipeline [1] - Another 45% will be used for marketing activities, channel expansion, and brand building for CU-40102 (topical finasteride spray) and CU-10201 (topical 4% minocycline foam) [1] - About 10% of the proceeds will be utilized for working capital and other general corporate purposes [1]
晶泰控股拟按每股9.28港元配股 最多净筹约26.3亿港元
Zhi Tong Cai Jing· 2025-08-29 00:27
Core Viewpoint - Jingtai Holdings (02228) announced a placement agreement to issue up to approximately 286 million placement shares at HKD 9.28 per share, aiming to raise approximately HKD 2.63 billion for various strategic initiatives [1] Group 1: Fundraising Details - The company plans to issue up to approximately 286 million shares through a placement agent [1] - Each placement share is priced at HKD 9.28, with total net proceeds expected to be around HKD 2.63 billion if fully subscribed [1] Group 2: Use of Proceeds - The raised funds will be utilized for continuous product iteration and upgrading, enhancing research and development capabilities, and solution capabilities [1] - The company aims to commercialize products and develop business by strengthening collaborations with external parties in similar and mutually beneficial industries [1] - Additional uses include potential acquisitions and investments, talent attraction and recruitment, working capital replenishment, and general corporate purposes [1]
晶泰控股(02228)拟按每股9.28港元配股 最多净筹约26.3亿港元
智通财经网· 2025-08-29 00:26
Core Viewpoint - Crystal Tech Holdings (02228) announced a placement agreement to issue up to approximately 286 million shares at a price of HKD 9.28 per share, aiming to raise approximately HKD 2.63 billion for various strategic initiatives [1] Group 1: Fundraising Purpose - The net proceeds from the share placement are intended for continuous product iteration and upgrading, enhancing research and development capabilities, and solution capabilities [1] - The funds will also support product commercialization and business development, strengthening collaborations with external parties and partners in similar and mutually beneficial industries [1] - Additional uses of the funds include potential acquisitions and investments, talent attraction and recruitment, working capital replenishment, and general corporate purposes [1]